The More Coffee Consumed Daily, the Lower the Risk of Death and Recurrence
Decaffeinated Coffee Also Linked to Improved Survival Rates
A large-scale observational study involving colorectal cancer patients has found that coffee consumption helps improve survival rates and reduce the risk of recurrence. The study observed that the more coffee patients consumed per day, the better their long-term prognosis tended to be, with the effect being particularly pronounced in patients with stage III colorectal cancer.
On January 27, Daejeon University Seoul Korean Medicine Hospital announced that Professor Cho Jonggwan’s research team at the East-West Cancer Center had confirmed the association between coffee intake and long-term prognosis in colorectal cancer patients through an observational study involving 5,442 participants.
According to the results, colorectal cancer patients who drank coffee had a higher overall survival rate and a lower risk of disease progression and recurrence compared to those who did not consume coffee. Notably, for each additional cup of coffee consumed per day, the risk of death and recurrence decreased by about 4%, and drinking three cups per day was associated with a risk reduction of approximately 12%.
This effect was most significant among patients with stage III colorectal cancer. In this group, coffee consumption was found to reduce the risk of death by more than 40%.
Furthermore, the study observed a correlation between decaffeinated coffee and improved survival and reduced recurrence risk. The research team explained that these positive effects of coffee are likely due to the combined action of various bioactive compounds such as polyphenols, rather than caffeine alone.
Professor Cho Jonggwan’s team stated, “This study provides evidence that can be referenced for long-term survival management and lifestyle guidance in colorectal cancer patients,” adding, “Further research is needed to establish a causal relationship between coffee consumption and prognosis in colorectal cancer patients.”
The study also included Professor Son Changgyu and resident Kim Junyeol from Daejeon University, and the findings were published online in 'Cancer Epidemiology, Biomarkers & Prevention' (CEBP), the official journal of the American Association for Cancer Research (AACR).
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
